BACKGROUND/OBJECTIVES: Lactobacillus helveticus LBK-16H-fermented milk products containing tripeptides isoleucine-prolineproline and valine-proline-proline lower blood pressure in hypertensive subjects using office and home blood pressure registration. The present study was aimed to evaluate the effects of two doses of these lactotripeptides on 24-h ambulatory blood pressure and lipidomics profiles in mildly hypertensive subjects. SUBJECTS/METHODS: In a randomized, double-blind, placebo-controlled parallel group study, 89 mildly hypertensive subjects ingested, after a 1-month run-in period, a fermented milk drink with 5 mg per day of lactotripeptides during 3 months, and a milk drink with 50 mg per day of lactotripeptides for the following 3 months, or a placebo milk drink without lactotripeptides. Ambulatory blood pressure (24 h) was recorded at baseline and at the end of the intervention periods. Lipidomics profiles were characterized before and after the 6-month intervention. RESULTS: After the second intervention period (50 mg per day of lactotripeptides), systolic and diastolic 24-h blood pressures decreased significantly in the peptide, but not in the placebo group. However, the treatment effects À 2.6 mm Hg (95% confidence interval (CI): À 5.7 to 0.4) in systolic and À 1.3 mm Hg (95% CI: À 3.4 to 0.8) in diastolic blood pressure did not reach statistic significance. Ingestion of 5 mg per day of lactotripeptides for 3 months did not lower blood pressure. The peptide group was dominated by decrease in multiple phospholipids (PL). CONCLUSIONS: Ingestion of fermented milk with daily dose of 50 mg of lactotripeptides appears to lower elevated blood pressure slightly from the baseline, but not significantly compared with the placebo group and to induce significant decreases in multiple PL.
INTRODUCTION
Hypertension is a well-identified risk factor for cardiovascular diseases, including coronary heart disease, peripheral arterial disease and stroke. The risk of these diseases can be lowered by antihypertensive treatment. Lifestyle modifications, such as healthy dietary habits, for example, restriction of salt and saturated fatty acids intake, and increases of low-fat dairy products and fiber, weight reduction and increase in physical activity are the primary strategy for the prevention and management of mild hypertension alone or parallel to drug treatment. 1, 2 An alternative among nutritional therapies for hypertension is the use of functional foods with antihypertensive effects, such as milk products containing lactotripeptides isoleucineproline-proline (Ile-Pro-Pro) and valine-proline-proline (Val-Pro-Pro). The lactotripeptides do not exist in milk in significant amounts, but are produced during fermentation or enzymatic hydrolysis of dairy proteins in specific processes, and by certain probiotic bacteria, 3, 4 and are absorbed partially into the circulation. 5, 6 Dairy products containing Ile-Pro-Pro and Val-ProPro (from 5 to 50 mg per day) have blood-pressure-lowering effects in mildly hypertensive subjects, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] although contradictory results have been reported. [19] [20] [21] Commercial products contain usually around 5 mg of peptides in recommended daily dose. Three recent meta-analyses [22] [23] [24] show mean reduction of systolic blood pressure 3.7-4.8 mm Hg and diastolic blood pressure 2.0-2.2 mm Hg.
Lipidomics is a system-based technique that can identify hundreds of cellular lipids and characterize alterations in their metabolism during the onset and progression of clinical diseases, as well as their response to the treatment. 25 As far as we know, the long-term effects of milk-derived lactotripeptides on lipidomics profiles have not previously been characterized. Furthermore, lipidomics might provide an insight into the mechanisms of the favorable cardiovascular effects (reduction of blood pressure, arterial stiffness) of bioactive peptides. 26 The aim of the present study was to evaluate in two successive 3 months' period the effects of a Lactobacillus helveticus LBK-16H-fermented milk drinks at two different doses of Ile-Pro-Pro and Val-Pro-Pro on blood pressure and lipidomics profiles in mildly hypertensive subjects, using 24-h ambulatory blood pressure measurement regarded as the most reliable method without white-coat hypertensive effect. 27 
SUBJECTS AND METHODS Subjects
A total of 396 subjects responded to the recruitment in media (local newspapers, radio) in the Helsinki, Finland area. Inclusion criteria were age between 25 and 55 years, and systolic blood pressure between 140 and 155 mm Hg, and diastolic blood pressure between 85 and 99 mm Hg at the beginning of the study in office measurement and after the run-in period in 24-h ambulatory measurement. Exclusion criteria were smoking, bloodpressure-lowering medication, secondary hypertension, unstable coronary artery disease, diabetes mellitus, malignant diseases, alcohol abuse, milk allergy, pregnancy or lactation. Of 216 subjects that entered the 4-week run-in period, 122 did not fulfill the tight criteria of hypertension in the 24-h blood pressure registration and were excluded. One subject from the peptide group and four from the placebo group withdrew from the study right after the run-in period. A total of 89 subjects (54 males and 35 females) were included and randomized to the placebo (n ¼ 44) and the peptide (n ¼ 45) groups. The demographic characteristics of the subjects at baseline are presented in Table 1 .
Design
This randomized placebo-controlled parallel group study was conducted in a double-blind fashion. Part of the crude cardiovascular findings has been published recently. 28 During the 4-week run-in period, the subjects received a daily 200 ml dose of a fermented milk product different from the peptide product or the placebo product. After the run-in period, subjects were randomly allocated to a peptide group that received Lactobacillus helveticus LBK-16H-fermented milk containing bioactive peptides or to a placebo group that received a placebo product with similar appearance and taste without the peptides. During the first 3 months of the intervention, the subjects were given daily 200 ml of the product with low dose of the tripeptides (5 mg per day) or placebo. For the following 3 months, independently of the first period's treatment effect, all subjects in the peptide group received two daily 200 ml doses of the test product with high dose of the lactotripeptides (50 mg per day) and the placebo group continued on the placebo drink. The new baseline was the blood pressure values in the second 24-h registration before the increase the dose.
The products were advised to be consumed in the morning during the first intervention period (one daily dose) and during the second intervention period, one dose in the morning and one in the evening (two daily doses). The subjects were asked to maintain their normal lifestyle and dietary habits, and register daily the use of the products and any adverse events. At the beginning and at the end of the interventions, the subjects were weighed and body mass index was calculated.
The study was approved by the Ethics Committee of the Joint Authority for the Hospital District of Helsinki and Uusimaa, Finland. Written informed consent was obtained from all participants.
Test products
The peptide drink during the first 3-month intervention period was L. helveticus LBK-16H-fermented, low-fat, lactose-free milk with a low concentration of peptides (Ile-Pro-Pro 1.2 mg/100 g and Val-Pro-Pro 1.3 mg/100 g; Valio Ltd., Helsinki, Finland) measured according to Masuda et al. 29 These amounts have been used in most clinical trials with commercial products. During the following 3-month period, a peptide product with higher concentrations was given (Ile-Pro-Pro 5.8 mg/100 g and Val-Pro-Pro 6.6 mg/100 g). The daily amount of lactotripeptides consumed was 5 mg during the first intervention period and 50 mg during the second intervention period. The placebo drink was fermented milk similar to the test drink, but without Ile-Pro-Pro and Val-Pro-Pro.
24-h ambulatory blood pressure measurement
At the beginning and at the end of the two intervention periods, blood pressure was registered with an automatic 24-h blood pressure recorder (Spacelab ABP 90207, Redmont, CA, USA) as described previously. 30 Readings were taken four times an hour during the daytime and twice an hour during the night. Single observations were excluded from the analyses because of low pulse pressure (below 15 mm Hg for systolic blood pressures lower than 120 mm Hg; below 20 mm Hg for systolic pressures higher than 120 mm Hg), high heart rates (X110), standing up or being awake during night times, or lying down during daytime. In addition, intensive physical exercise was not allowed during the recordings. 30 The recordings were analyzed in a fully blinded fashion. In the analysis, daytime was defined as hours 0600 to 2200 h, and night time as hours 2200 to 0600 h.
Blood sampling
Blood samples were drawn at the beginning and at the end of the interventions (three times during the study) after an overnight (12-h) fast. Total cholesterol, high-density lipoprotein cholesterol and triglycerides were measured enzymatically, and low-density lipoprotein cholesterol was calculated by the Friedewald equation. 31 
Lipidomics
Lipidomics profiles were randomly characterized at the baseline and after the 6-month intervention period from randomly selected 10 subjects from the peptide intervention group and 10 subjects from the placebo group. The global lipidomics platform based on ultra performance liquid chromatography coupled to high-resolution mass spectrometry was utilized. Because profile changes across a diverse range of lipids such as phospholipids (PL) and neutral lipids were of interest, the experiment was performed in positive ion mode.
An aliquot (10 ml) of an internal standard mixture containing 11 lipid classes, and 0.05 M sodium chloride (10 ml) was added to plasma samples (10 ml). The lipids were extracted with chloroform/methanol (2:1, 100 ml). A standard mixture containing three labeled standard lipids was added (10 ml) to the extracts. Three replicates of each sample were analyzed in a randomized order.
Lipid extracts were analyzed on a Waters Q-Tof Premier mass spectrometer combined with an Acquity UPLC (Waters Inc., Milford, MA, USA). The column, which was kept at 50 1C, was an Acquity UPLC BEH C18 10 Â 50 mm with 1.7 mm particles. The binary solvent system included (A) 1% 1 M NH 4 Ac, 0.1% HCOOH in water and (B) 1% 1 M NH 4 Ac, 0.1% HCOOH in acetonitrile/isopropanol (5:2; Rathburn Chemicals Ltd, Walkerburn, Scotland). The gradient started from 65% A/35% B, reached 100% B in 6 min and remained there for the next 7 min. The total run time including a 5-min re-equilibration step was 18 min. The flow rate was 200 ml/min, and the injected amount was 0.75 ml. The temperature of the sample organizer was set at 10 1C.
The lipid profiling was carried out on Waters Q-Tof Premier mass spectrometer using ESI þ mode. The data were collected at mass range of m/z 300-1200 with a scan duration of 0.2 s. The source temperature was set at 120 1C and nitrogen was used as the desolvation gas (800 l/h) at 250 1C. The voltages of the sampling cone and capillary were 39 V and 3.2 kV, respectively. Reserpine (50 mg/l; product No. R0875, Sigma Aldrich, St Louis, MO, USA) was used as the lock spray reference compound (5 ml/min; 10 s scan frequency).
Data were processed using MZmine software version 0.60. 32 Lipids were identified using an internal spectral library or with tandem mass spectrometry. The normalization of lipidomics data was performed as follows: all monoacyl lipids, except cholesterol esters, were normalized with GPCho(17:0/0:0), all diacyl lipids except ethanolamine PL were normalized with GPCho(17:0/17:0), ceramides with Cer(d18:1/17:0), the diacyl ethanolamine PL with GPEtn(17:0/17:0), and trigycerides (TG) and cholesterol esters with TG(17:0/17:0/17:0). Unidentified molecular species 
Statistical analysis
Blood pressure. The results are given as mean of 24-h registration with s.d. or 95% confidence intervals (95% CI). The changes within groups were analyzed using paired samples t-test. The treatment effect was defined as mean difference between groups in blood pressure changes. Analysis of covariance with baseline (first intervention period) or 3 months' (second intervention period) value as a covariate was performed to compare blood pressure changes between groups. Mixed models with exchangeable covariance structure were used to estimate 95% CI for the mean hourly blood pressure. P-valueso0.05 or less were regarded significant.
Lipidomics. Principal components analysis and partial least squares discriminant analysis were utilized as a modeling methods for clustering and discrimination. 33 Random subsets cross-validation method and Q 2 scores were used to develop the models. The variable importance in the projection values were calculated to identify the most important molecular species for the clustering of specific groups. Multivariate analyses were performed using Matlab version 7.2 (Mathworks, Natick, MA, USA) and PLS Toolbox version 4.0 Matlab package (Eigenvector Research, Wenatchee, WA, USA).
Comparisons between the levels of selected molecular species were performed using the paired Wilcoxon test. The univariate analyses to compare changes for individual lipids were performed using two-sided or paired t-test.
The correlations between lipidomic analysis and high-density and lowdensity lipoprotein cholesterol levels were calculated using Spearman's correlation.
RESULTS

Blood pressure
In the Figures 1 and 2 , the mean hourly blood pressures during 24-h ambulatory registration with 95% CIs at baseline and after 3 and 6 months' are presented. The smaller peptide dose (5 mg per day) had no blood-pressure-lowering effect during 3 months intervention, whereas in the placebo group, 24-h values in both systolic and diastolic blood pressure showed a slight but significant reduction; however, between the treatment groups, no significant difference was found ( Table 2) . Table 3 shows blood pressures at 3 months' baseline and changes from 3 to 6 months in the peptide (50 mg per day) and in the placebo groups. Both systolic and diastolic blood pressures were clearly lower during night than during daytime. The 24-h systolic and diastolic blood pressure, and diastolic blood pressure at daytime decreased significantly in the peptide group, whereas no changes were observed in the placebo group. The treatment effects for systolic and diastolic 24-h blood pressure were À 2.6 mm Hg (95% CI: À 5.7 to 0.4) and À 1.3 mm Hg (95% CI: À 3.4 to 0.8), respectively, but neither of these were statistically significant. Mean arterial pressure 24-h and daytime pressure decreased significantly in the peptide group, whereas no changes were observed in the placebo group, but the differences between the groups were not significant. There were no changes in pulse pressure. There were no differences in the changes of blood pressures between genders, even though generally the mean decreases from the baseline were more marked in men (data not shown).
Lipidomics and lipoproteins
The lipidomics analysis led to 218 identified lipid species, corresponding to 15 different lipid classes. Principal components and partial least squares discriminant analyses on baseline lipidomics data revealed differences between groups. Specifically, concentrations of several triacylglycerol species were higher in the placebo group. After 24 weeks, 25 triacylglycerol species were increased (Po0.05, paired t-test) in the placebo group. The peptide group was dominated by decrease in multiple PL, including phosphatidylcholines and phosphatidylethanolamines (Po0.05). Figure 3 shows 20 most changed species within each group and their respective differences compared with the other group. There were no differences between the groups in serum cholesterol values. The changes in PL were not associated with high-density or low-density lipoprotein cholesterol levels (data not shown).
Adverse events Adverse events were registered during the intervention periods. In the peptide group, two subjects reported diarrhea, bloating and restless legs. In the placebo group, four subjects reported nausea, diarrhea and vomiting. All of the symptoms were mild, occurred only occasionally and were apparently not related to the treatments.
Other variables
The subjects reported that they did not change their dietary habits or physical activity during the interventions, and the compliance was excellent. There were no marked changes in the body weight or body mass index during the study in either of the groups.
DISCUSSION
In this randomized, double-blind, placebo-controlled study, longterm use of L. helveticus LBK-16H-fermented milk product with 5 and 50 mg per day of lactotripeptides Ile-Pro-Pro and Val-Pro-Pro reduced the 24-h ambulatory systolic and diastolic blood pressure by 2.6 and 1.3 mm Hg, respectively, compared with the placebo. Even though small and statistically not significant between the treatment groups, this size difference may be of clinical significance. It has been estimated that a decrease in systolic blood pressure by 2 mm Hg would reduce the risk for stroke by 4.2% and risk for myocardial infarction by 3.8%. 34 In addition, we demonstrated that long-term ingestion of lactotripeptides led to significant decreases in multiple PL in plasma samples.
Earlier, a meta-analysis of 12 randomized, controlled trials found that ingestion of 2.6-5.6 mg per day of lactotripeptides Ile-Pro-Pro and Val-Pro-Pro for 4-21 weeks decreases systolic and diastolic blood pressures by 4.8 and 2.2 mm Hg, respectively. 23 Another meta-analysis by Pripp 22 included intervention studies on both lactotripeptides and other peptides derived from food, and found a significant effect on systolic blood pressure of À 5.1 mm Hg and diastolic blood pressure of À 2.4 mm Hg. A very recent metaanalysis by Cicero et al. 24 on 18 placebo-controlled trials, with altogether almost 1700 subjects, showed as a pooled effect of peptide-containing products a reduction of À 3.7 mm Hg in systolic and À 2.0 mm Hg diastolic pressure. On the other hand, three recent intervention studies showed no significant decreases in blood pressure after ingestion of 4.6-14 mg per day of lactotripeptides for 4-8 weeks. [19] [20] [21] Several variables, such as lactotripeptide dose, duration of the intervention and differences in study designs (for example, level of the blood pressure (hypertension/ normotension)), subjects, (for example, ethnic differences) and test products, (for example, isomerisation of the peptides) could explain the variable responses to the lactotripeptides.
There are several strengths in the present study. It was a randomized, double-blind, placebo-controlled study. Two doses of lactotripeptides (5 and 50 mg per day) were used, and the durations of the interventions were long, 3 months with each dose, which, on the basis of our earlier studies, 9, 13 were estimated to be sufficient for detecting any effect on blood pressure. The final study population was quite homogenous because of the tight criteria for hypertension in the 24-h registration. The subjects followed the instructions carefully, the compliance was excellent and the dropout rates were low. In addition, the subjects were able to maintain their dietary habits and physical activity level stable. No significant changes were seen in the body weight during the 6-month intervention period.
We used 24-h ambulatory blood pressure registration, considered as the 'golden standard' method showing blood pressure behavior over a 24-h period during normal daily activities without a white-coat effect. 35 In a recent study, the antihypertensive effect of milk peptides was demonstrated for office blood pressure, but not for home or ambulatory blood pressure measurements. 36 It was suggested that the effect of lactotripeptides may be only short-term and not sufficient to produce significant changes in 24-h blood pressure. 36 In addition, ambulatory blood pressure values are lower than office readings, and the blood-pressure-lowering effect of lactotripeptides is easier to demonstrate when the blood pressure is higher. 12, 14, 23 In the present study, 24-h systolic and diastolic blood pressure decreased significantly only in the peptide group ( À 2.3 and À 1.8 mm Hg, respectively), but the difference between the groups was not statistically significant. As seen in the present and other trials (see meta-analyses [22] [23] [24] ), the effect of lactotripeptides varies individually from subject to subject, which may result in clinically significant mean reductions in blood pressure not reaching statistical significance in this number of study population.
As far as we know, the possible effects of lactotripeptides on lipidomics profiles have not been studied before. We characterized the plasma lipidomics profiles in 10 subjects from the peptide group and 10 subjects from the placebo group at baseline and after the 6-month intervention period. As a limitation of our study, there were significant differences between the groups already at baseline, with significant upregulation of multiple triacylglycerols in the placebo group. This makes the interpretation of the results difficult.
After the intervention period, many significant changes in lipidomics profiles were seen in both groups. In the placebo group, 25 triacylglycerol species were significantly increased after Figure 3 . Fold changes (mean values, 6 month (3 months with the daily dose of 5 mg following 3 months with daily dose of 50 mg of the peptides) vs baseline) for top 10 lipid species within the peptide (n ¼ 10) and placebo groups (n ¼ 10). P-values were calculated using paired samples t-test (*Po0.05, **Po0.01, ***Po0.001).
6 months, which may be because of even minor dietary changes. The subjects did not report changes in diet or lifestyle, but it has been shown that triacylglycerols are very sensitive to daily variation of the diet. 37 The peptide group was dominated by decrease in multiple PL, such as phosphatidylcholines and phosphatidylethanolamines. These PL are building blocks of lipoproteins, 38 and thus, a correlation analysis was made to find out whether the decreases in PL were associated with highdensity or low-density lipoprotein cholesterol levels. However, no associations were found. The significance of the changes in PL needs to be investigated in the future. In the present study, lipidomics did not reveal distinct intervention-induced changes that could be attributed to beneficial cardiovascular effects described earlier. In the future clinical trials, more attention should be paid to endothelium-derived lipid mediators, such as arachidonic acid and its metabolites, for example, endoperoxides and prostacyclin.
The present study confirmed our earlier finding 13 that even large amounts of lactotripeptides are well tolerated. Mild adverse effects occurred occasionally in both groups and were considered not to be because of the active treatment.
In conclusion, we were not able to show significant difference in blood-pressure-lowering effect with long-term intake of Lactobacillus helveticus-fermented milk product with added lactotripeptides (50 mg per day) compared with placebo group. However, this high dose seemed to lower blood pressure in slightly hypertensive subjects from the baseline without adverse effects. Lipidomic analysis showed that the ingestion of the lactotripeptides was characterized by decrease in multiple PL. We cannot exclude the possibility that the observed baseline differences in triacylglycerols, as well as small sample size in lipidomic analysis may have masked other potential changes across different lipid classes.
CONFLICT OF INTEREST
TJ is and RK was an employee of Valio Ltd. HV was consulting for Valio Ltd, and at present Santen Ltd and MSD Finland Ltd, Finland. Valio Ltd compensed LN and SJ for their working time.
